EGFR and cancer: Ramirez et al. demonstrated in EGFR-addicted, erlotinib-sensitive NSCLC cell lines the emergence of small subpopulations of cancer cells that became resistant to erlotinib and originated from a common clone, through the bottleneck of drug-tolerant, slow-growing “persisters” [280].